Is immunotherapy the next best option for a patient with metastatic translocation-associated renal cell carcinoma (TFEB rearrangement) after progression on 1st line sunitinib and 2nd line everolimus/lenvatinib?

One of the challenges we all deal with every day is making clinical decisions in the absence of real evidence to guide us. Translocation-associated renal cell carcinoma (TFEB rearrangement) is of course a very rare entity and any inference regarding response or lack-thereof to any therapeutic interv...

Data are very limited regarding activity of IO in TFE RCC, although I believe there are some reports of activity on an anecdotal basis. Despite these limitations, however, this patient has received other classes of medications and barring contraindications I would favor IO-based therapy in this pati...

I would be very skeptical of immunotherapy success in this situation. If I understand this tumor is driven by a specific fusion and the subsequent production of presumably the downstream proteins is driving this tumor. Its occurrence in younger age is typical of translocation driven tumors, and it o...